Znf346 Antibody

What is ZNF346 and why is it relevant to research?

ZNF346 is a nucleolar zinc finger protein that preferentially binds to double-stranded (ds) RNA or RNA/DNA hybrids rather than DNA alone. The protein contains four CH-type zinc finger motifs connected by long (28-38) amino acid linker sequences. ZNF346 is ubiquitously expressed across tissues and primarily localizes to the nucleus, especially the nucleolus. It may be involved in cell growth and survival, and recent research has identified it as a potential biomarker in hepatocellular carcinoma (HCC) and colorectal cancer (CRC). ZNF346 plays a role in protecting neurons by inhibiting cell cycle re-entry via stimulation of p21 gene expression, making it relevant for both cancer and neuroscience research .

What are the known isoforms of ZNF346 and how might this affect antibody selection?

Three isoforms of ZNF346 are known to exist. When selecting antibodies, it's crucial to consider which isoforms you need to detect. Some antibodies, such as those targeting the C-terminal region, will recognize only the two longest isoforms, while others may detect all three isoforms. For comprehensive studies, you might need multiple antibodies targeting different epitopes. Always verify in the antibody documentation which isoforms are recognized to ensure your experimental design aligns with your research questions .

What applications are ZNF346 antibodies validated for?

ZNF346 antibodies have been validated for multiple applications, including:

• Western Blotting (WB) (typically at dilutions of 1:500-1:2000)

• Enzyme-Linked Immunosorbent Assay (ELISA) (typically at 1 μg/ml)

• Immunofluorescence (IF) (typically at dilutions of 1:50-1:200)

• Immunohistochemistry on paraffin-embedded sections (IHC-P)

• Immunoprecipitation (IP)

The optimal dilution may vary between antibody sources and specific applications, so optimization is essential for each experimental context .

How should I optimize Western blot protocols for ZNF346 detection?

For optimal Western blot detection of ZNF346:

• Sample preparation: Use standard cell lysis buffers with protease inhibitors. ZNF346 has a calculated molecular weight of approximately 33 kDa but is typically observed at 36 kDa on SDS-PAGE.

• Antibody dilution: Start with a 1:1000 dilution for primary antibody incubation. Most suppliers recommend ranges between 1:500-1:2000.

• Incubation conditions: Overnight incubation at 4°C typically yields the best results.

• Controls: Include positive controls from cell lines known to express ZNF346 (most human cell lines express it as it's ubiquitously expressed).

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Expected band size: Approximately 36 kDa, though the calculated weight is 33 kDa.

Western blot validation has been performed on various cell lines, so check the antibody documentation for specific positive controls that match your experimental system .

What considerations are important for immunohistochemistry applications with ZNF346 antibodies?

When performing immunohistochemistry with ZNF346 antibodies:

• Fixation: Standard formalin fixation and paraffin embedding protocols are suitable.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended.

• Antibody dilution: Start with a 1:100 dilution (ranges from 1:50-1:200 are common).

• Expected localization: Primary nuclear staining with nucleolar enrichment.

• Positive controls: Brain tissue and most epithelial tissues should show positive staining.

• Negative controls: Omit primary antibody or use tissue known to have minimal ZNF346 expression.

• Counterstaining: Hematoxylin provides good nuclear contrast for visualizing ZNF346 localization.

Remember that ZNF346 is ubiquitously expressed but at varying levels across tissues, so appropriate control selection is crucial for accurate interpretation .

How can ZNF346 antibodies be used to study its role in cancer progression?

ZNF346 has shown promise as a biomarker in cancer research, particularly in hepatocellular carcinoma (HCC) and colorectal cancer (CRC). To study its role in cancer progression:

What is the significance of ZNF346 autoantibodies in cancer detection, and how can they be studied?

ZNF346 autoantibodies have emerged as potential biomarkers for cancer detection, particularly in colorectal cancer:

• Serum-based ELISA: Develop or use existing ELISA protocols to detect autoantibodies against ZNF346 in patient sera. In colorectal cancer studies, ZNF346 autoantibodies were detected in 15.6% of CRC patients compared to 5.7% in non-cancer controls.

• Multiplex testing: Combine ZNF346 with other zinc finger protein antibodies (like ZNF638, ZNF700, and ZNF768) to improve diagnostic sensitivity. A four-marker panel increased sensitivity to 41.7% while maintaining 91.4% specificity.

• Stage-independent detection: Evaluate the presence of autoantibodies across different cancer stages. Research shows ZNF346 autoantibodies appear independently of disease stage, suggesting utility for early detection.

• Epitope analysis: Investigate which regions of ZNF346 are most immunogenic. The classical C2H2 zinc finger motif has been identified as a potential immunogenic determinant in some zinc finger proteins.

• Clinical validation: Test autoantibody detection in large, multi-center cohorts to validate clinical utility, comparing against current screening methods like FOBT.

This approach offers a complementary method to existing cancer screening programs and may help detect non-symptomatic colorectal cancer patients in both early and advanced stages .

What approaches can be used to study ZNF346's interaction with RNA/DNA hybrids?

To investigate ZNF346's preferential binding to double-stranded RNA or RNA/DNA hybrids:

• Co-immunoprecipitation with RNA/DNA analysis:

  • Perform anti-ZNF346 immunoprecipitation to pull down the protein

  • Extract and analyze bound nucleic acids using sequencing approaches

  • Compare binding to different nucleic acid structures (dsRNA, RNA/DNA hybrids, dsDNA)

• Electrophoretic Mobility Shift Assay (EMSA):

  • Use purified ZNF346 protein (or nuclear extracts containing ZNF346)

  • Test binding to labeled dsRNA or RNA/DNA hybrid probes

  • Confirm specificity using unlabeled competitors and anti-ZNF346 antibodies

• Chromatin Immunoprecipitation (ChIP) with RNA component analysis:

  • Perform ChIP using anti-ZNF346 antibodies

  • Analyze both DNA and RNA components of the precipitated material

  • Determine if ZNF346 preferentially associates with genomic regions producing RNA/DNA hybrids

• Mutational analysis combined with binding studies:

  • Utilize ZNF346 mutants targeting zinc finger domains

  • Compare binding capabilities to wild-type protein using immunoprecipitation

  • Correlate with nucleolar localization to confirm the dual role of zinc finger domains

These approaches leverage antibody-based methods to reveal fundamental aspects of ZNF346 biology, particularly its preference for RNA/DNA hybrid structures over DNA alone and the importance of its zinc finger domains for both binding and localization .

What are common pitfalls when detecting ZNF346 by Western blot and how can they be addressed?

When working with ZNF346 antibodies in Western blot applications, researchers may encounter these common issues:

• Multiple bands or unexpected band sizes:

  • Issue: The calculated molecular weight of ZNF346 is 33 kDa, but it typically appears at 36 kDa. Additional bands may represent different isoforms or post-translational modifications.

  • Solution: Verify which isoforms your antibody recognizes. Some antibodies detect only the two longest of the three known isoforms. Include controls with known ZNF346 expression patterns.

• Weak signal:

  • Issue: Low endogenous expression or inefficient protein transfer.

  • Solution: Increase protein loading (30-50 μg recommended), optimize antibody concentration (try 1:500 instead of 1:1000), and extend exposure time. PVDF membranes may provide better results than nitrocellulose for this protein.

• High background:

  • Issue: Non-specific binding or insufficient blocking.

  • Solution: Use 5% BSA instead of milk for blocking, increase washing steps, and optimize secondary antibody dilution. Consider using specialized blocking reagents specifically designed for zinc finger proteins.

• Cross-reactivity with other zinc finger proteins:

  • Issue: Zinc finger domains share structural similarities.

  • Solution: Use antibodies specifically validated for minimal cross-reactivity with other ZNF family members. ZNF346 antibodies targeting the C-term region are often more specific.

• Inconsistent results between antibody lots:

  • Issue: Lot-to-lot variability in polyclonal antibodies.

  • Solution: Maintain detailed records of antibody lots used, and re-validate new lots against known positive controls before conducting critical experiments .

How can I differentiate between nuclear and nucleolar localization of ZNF346 in immunofluorescence experiments?

ZNF346 primarily localizes to the nucleus with enrichment in nucleoli. To clearly differentiate these patterns:

• Co-staining strategy:

  • Use anti-ZNF346 antibody alongside established nucleolar markers (e.g., fibrillarin, nucleolin)

  • Include a general nuclear stain like DAPI or Hoechst

  • Analyze co-localization with nucleolar markers quantitatively

• High-resolution imaging:

  • Use confocal microscopy with optical sectioning

  • Apply deconvolution algorithms to enhance resolution

  • Consider super-resolution techniques for detailed co-localization studies

• Quantitative analysis:

  • Measure fluorescence intensity ratios between nucleolar regions and the nucleoplasm

  • Apply line-scan analysis across nuclei to generate intensity profiles

  • Use co-localization coefficients (Pearson's or Mander's) to quantify overlap with nucleolar markers

• Controls and validation:

  • Include cells treated with RNA polymerase I inhibitors (e.g., actinomycin D at low doses), which disrupt nucleolar structure

  • Compare wild-type ZNF346 localization with mutants lacking zinc finger domains, which are required for nucleolar localization

• Recommended antibody conditions:

  • Use 1:100 dilution for primary antibody (range: 1:50-1:200)

  • Apply appropriate antigen retrieval for fixed specimens

  • Block with 1-5% BSA in PBS for optimal results

These approaches will allow precise characterization of ZNF346's subnuclear distribution and help distinguish between general nuclear and specific nucleolar localization patterns .

How can ZNF346 antibodies be utilized to investigate its potential role in inflammation and immune regulation?

Recent research has identified connections between ZNF346 and immune regulation, particularly in cancer contexts. Here are methodological approaches to investigate this relationship:

• Immune cell correlation studies:

  • Use multiplex immunohistochemistry with ZNF346 antibodies alongside immune cell markers

  • Analyze spatial relationships between ZNF346-expressing cells and immune cell infiltrates

  • Quantify correlations between ZNF346 expression levels and immune cell densities

• Cytokine production analysis:

  • Perform ZNF346 knockdown or overexpression followed by cytokine profiling

  • Use flow cytometry with intracellular staining for ZNF346 and cytokine production

  • Investigate changes in inflammatory signaling pathways using phospho-specific antibodies

• Immune checkpoint relationship investigation:

  • Analyze co-expression patterns of ZNF346 and immune checkpoint genes

  • Examine effects of ZNF346 modulation on checkpoint molecule expression

  • Test whether ZNF346 levels predict response to immune checkpoint inhibition therapy

• Inflammation model systems:

  • Use antibodies to track ZNF346 expression changes during inflammatory processes

  • Investigate ZNF346 expression in chronic inflammation and its progression to cancer

  • Study HBV-induced inflammation specifically, as ZNF346 shows associations with HBV infection

This research would build on findings that ZNF346-high expression correlates with immunosuppressive cells (M2 macrophages, Tregs, MDSCs), inflammatory cytokines, and immune checkpoint genes, potentially explaining its association with poor immunotherapy efficacy in HCC .

What methods could be developed to target ZNF346 therapeutically, and how would antibodies facilitate this research?

While ZNF346 antibodies are currently research tools, their use could facilitate therapeutic development through these approaches:

• Target validation and mechanism studies:

  • Use antibodies to confirm ZNF346 expression in patient samples before treatment

  • Track changes in ZNF346 levels during disease progression and treatment response

  • Employ antibodies in mechanistic studies to understand how ZNF346 contributes to pathology

• Drug screening support:

  • Develop cell-based assays using antibodies to measure ZNF346 protein levels or localization

  • Screen compound libraries for molecules that modulate ZNF346 expression or function

  • Use antibodies to verify target engagement of potential therapeutic compounds

• Therapeutic antibody development pipeline:

  • Utilize research antibodies to identify accessible epitopes for therapeutic targeting

  • Develop antibody derivatives that can enter cells to target nucleolar ZNF346

  • Test antibody-drug conjugates targeting cancer cells with high ZNF346 expression

• Biomarker development:

  • Establish standardized immunohistochemistry protocols to stratify patients by ZNF346 expression

  • Develop companion diagnostics for future ZNF346-targeting therapies

  • Create assays detecting ZNF346 autoantibodies as non-invasive cancer screening tools

• RNA-based therapeutic targeting:

  • Use antibodies to validate the effectiveness of siRNA or antisense oligonucleotides targeting ZNF346

  • Monitor protein knockdown efficiency following genetic interventions

  • Assess downstream effects of ZNF346 inhibition on proliferation and migration

These approaches would be particularly relevant in HCC and colorectal cancer contexts, where ZNF346 knockdown has already demonstrated anti-proliferative and anti-migratory effects, suggesting therapeutic potential .

How can integrated multi-omics approaches incorporate ZNF346 antibody-based detection methods?

Modern research increasingly employs integrated multi-omics approaches. ZNF346 antibodies can be incorporated into these strategies through:

• Chromatin Immunoprecipitation followed by Sequencing (ChIP-seq):

  • Map genomic binding sites of ZNF346 using specific antibodies

  • Integrate with RNA-seq data to correlate binding with transcriptional changes

  • Perform differential binding analysis between normal and disease states

• Proteomics integration:

  • Use antibodies for immunoprecipitation followed by mass spectrometry (IP-MS)

  • Identify ZNF346 protein interaction networks in different cellular contexts

  • Compare interactomes between normal and disease states

• Spatial transcriptomics/proteomics correlation:

  • Combine ZNF346 immunohistochemistry with spatial transcriptomics technologies

  • Map relationships between ZNF346 protein expression and local transcriptional programs

  • Analyze spatial relationships with key pathway components and immune markers

• Single-cell approaches:

  • Integrate single-cell RNA-seq with antibody-based protein detection (CITE-seq)

  • Identify cell populations with distinct ZNF346 expression patterns

  • Correlate with cell states, differentiation trajectories, and immune phenotypes

• Functional genomics validation:

  • Use antibodies to validate CRISPR screens targeting ZNF346 regulatory networks

  • Confirm protein-level changes following genetic perturbations

  • Correlate functional outcomes with mechanistic insights from multi-omics data

These integrated approaches would provide a comprehensive view of ZNF346 biology beyond what can be achieved with any single method, potentially revealing new therapeutic opportunities and mechanistic insights, particularly in cancer contexts where ZNF346 shows prognostic significance .

What are the detailed specifications of commercially available ZNF346 antibodies?

The following table summarizes key specifications of commercially available ZNF346 antibodies based on manufacturer data:

This information helps researchers select the most appropriate antibody for their specific experimental requirements, considering factors like species compatibility, application needs, and epitope targeting .

How has the specificity of ZNF346 antibodies been validated in research contexts?

Validation of ZNF346 antibodies has been conducted through multiple approaches:

• Western blot validation:

  • Testing against recombinant ZNF346 protein

  • Comparison of band patterns across multiple cell lines with known ZNF346 expression

  • Demonstration of a predominant band at approximately 36 kDa (calculated MW: 33 kDa)

  • Knockdown validation showing reduction in signal intensity following siRNA treatment

• Cross-reactivity assessment:

  • Testing against related zinc finger family members

  • Most antibodies are predicted not to cross-react with other ZNF family proteins

  • Specificity for specific isoforms (e.g., many antibodies recognize only the two longest of three known isoforms)

• Immunohistochemistry validation:

  • Demonstration of expected nuclear/nucleolar staining pattern

  • Consistent staining across multiple tissue types (reflecting ubiquitous expression)

  • Positive controls in tissues with known high expression

  • Negative controls using primary antibody omission

• Immunofluorescence confirmation:

  • Co-localization with known nucleolar markers

  • Confirmation of nuclear export patterns with cellular fractionation studies

  • Validation in multiple cell types showing consistent localization patterns

• Functional validation:

  • Demonstration of antibody utility in immunoprecipitation experiments

  • Correlation of antibody signals with functional outcomes in knockdown studies

  • Confirmation of expected changes in protein levels following experimental manipulations

These validation approaches ensure that the antibodies reliably detect ZNF346 with minimal cross-reactivity, providing confidence in experimental results across multiple applications .

How is ZNF346 research expected to evolve, and what role will antibody-based methods play?

ZNF346 research is poised for significant developments in several areas:

• Cancer biomarker validation: Larger clinical studies will likely validate ZNF346 as a prognostic and predictive biomarker, particularly in HCC and CRC. Standardized antibody-based assays will be crucial for consistent patient stratification across clinical settings.

• RNA biology mechanisms: As a protein that preferentially binds RNA/DNA hybrids, ZNF346 may emerge as an important regulator of RNA processing, R-loops, or non-coding RNA function. Antibodies will enable RNA-immunoprecipitation and sequencing approaches to map its RNA interactions genome-wide.

• Therapeutic targeting: Given its association with cancer cell proliferation and migration, ZNF346 may become a therapeutic target. Antibody-based screening assays will help identify small molecule inhibitors or develop RNA-based therapeutics targeting ZNF346.

• Immunotherapy connections: The correlation between ZNF346 expression and immunosuppressive tumor microenvironments suggests potential applications in immunotherapy response prediction. Antibody-based tissue analyses will help stratify patients for immunotherapy trials.

• Neuroscience applications: ZNF346's role in protecting neurons through p21 regulation warrants further investigation in neurodegenerative disease contexts. Sensitive antibody detection methods will track ZNF346 expression in neuronal models and patient samples.